Outcome of Extremely Preterm Infants Who Received Systemic Postnatal Corticosteroid for Bronchopulmonary Dysplasia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-01-01

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bronchopulmonary dysplasia is a complication of prematurity. Postnatal corticosteroid is used to treat the inflammatory part of this pathology, in particular to wean premature infants from the ventilator at the end of the first month of life. However, this therapy remains controversial because it may induce suboptimal neurocognitive development. Parents of infants who receive postnatal corticosteroid should be provided with information about the risks. The objective of our work was to evaluate the respiratory, neurodevelopmental and growth outcomes at 24 months corrected age of extremely preterm infants who received postnatal corticosteroid.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PREMILOC Trial to Prevent Bronchopulmonary Dysplasia in Very Preterm Neonates

NCT00623740

Bronchopulmonary Dysplasia

COMPLETED PHASE3

Respiratory Outcome at Adolescence of Very Low Birthweight Infants

NCT01424553

Premature Baby 26 to 32 Weeks Bronchopulmonary Dysplasia

COMPLETED NA

Genetic Susceptibility for Bronchopulmonary Dysplasia in Preterm Infants

NCT00904774

Bronchopulmonary Dysplasia

UNKNOWN

Hydrocortisone for BPD

NCT01353313

Infant, Newborn Infant, Small for Gestational Age Infant, Very Low Birth Weight +2 more

COMPLETED PHASE3

Mesenchymal Stem Cell Therapy for Bronchopulmonary Dysplasia in Preterm Babies

NCT02443961

Bronchopulmonary Dysplasia

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bronchopulmonary Dysplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Preterm infants who received postnatal corticosteroid for bronchopulmonary dysplasia

Corticosteroids used are hydrocortisone (as first-line therapy) and betamethasone (in situations of particular severity)

Evaluation at 24 months corrected age: respiratory outcome, Neurodevelopmental outcome, Growth outcome

Intervention Type DRUG

Data concerning the 24 months corrected age outcomes were collected from the medical records of the ECL'AUR preterm infants follow-up network.

Preterm infants who did not receive postnatal corticosteroid for bronchopulmonary dysplasia

No corticosteroids

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Evaluation at 24 months corrected age: respiratory outcome, Neurodevelopmental outcome, Growth outcome

Data concerning the 24 months corrected age outcomes were collected from the medical records of the ECL'AUR preterm infants follow-up network.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Extremely preterm infants less than 29 weeks' gestation
* Infants hospitalized for at least the first 30 days of life in the neonatology department of the Croix-Rousse Hospital in Lyon
* Infants born between January 1, 2013 and December 31, 2016

Exclusion Criteria

* Infants with a congenital heart, lung or brain malformation
* Infants with a neuromuscular disease
* Infants with a genetic disorder
* Infants who died before the age of 24 months corrected age
* Infants lost to follow-up or with incomplete data at 24 months corrected age

Eligible Sex

ALL

Accepts Healthy Volunteers

No